Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335140 · ClinicalTrials.gov registry record · Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00335140 is a Phase 2 study that was terminated before completion, run by Eastern Cooperative Oncology Group. The registered enrollment target is 26 participants.
The verdict
NCT00335140, a Phase 2 study, was terminated before completion, sponsored by Eastern Cooperative Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma.
Interventions
- DRUG Leucovorin
- DRUG Dexamethasone
- BIOLOGICAL Rituximab
- DRUG Cytarabine
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-08-23 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00335140
The ClinicalTrials.gov registry entry for NCT00335140 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Leucovorin is the first listed.
NCT00335140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00335140 about?
NCT00335140 is a clinical study titled "Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma". RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leu...
What is the current status of trial NCT00335140?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2007-08-23. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00335140?
The interventions under investigation include: Leucovorin (DRUG), Dexamethasone (DRUG), Rituximab (BIOLOGICAL), Cytarabine (DRUG), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT00335140?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.